Adolescent Risperidone treatment alters protein expression associated with protein trafficking and cellular metabolism in the adult rat prefrontal cortex

Proteomics

Volumn 14, Issue 12, 2014, Pages 1574-1578

  Farrelly, Lorna A ^a   Dicker, Patrick ^b   Wynne, Kieran ^c   English, Jane ^a   Cagney, Gerard ^c   Föcking, Melanie ^a   Cotter, David R ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antipsychotics; Biomedicine; LC MS MS; Prefrontal cortex; Risperidone

Indexed keywords

PROTEIN; RISPERIDONE; NEUROLEPTIC AGENT; PROTEOME;

ADOLESCENCE; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL METABOLISM; CONTROLLED STUDY; CYTOSKELETON; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; MITOCHONDRION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; ANIMAL; DRUG EFFECTS; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; PROTEIN DATABASE; PROTEOMICS; TANDEM MASS SPECTROMETRY; WISTAR RAT; BRAIN MITOCHONDRION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL PHYSIOLOGICAL PHENOMENA; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; MALE; PREFRONTAL CORTEX; PROTEIN TRANSPORT; PROTEOME; PROTEOMICS; RATS; RATS, WISTAR; RISPERIDONE; TANDEM MASS SPECTROMETRY;

EID: 84902208559     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300466     Document Type: Article

References (38)

1. Seeman, P., Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47, 27-38.
2. Miyamoto, S., Duncan, G. E., Marx, C. E., Lieberman, J. A., Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79-104.
3. Arnt, J., Skarsfeldt, T., Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18, 63-101.
4. Holmes, E., Tsang, T. M., Huang, J. T., Leweke, F. M. et al., Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3, e327.
5. Telford, J. E., Bones, J., McManus, C., Saldova, R. et al., Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins. J. Proteome Res. 2012, 11, 3743-3752.
6. Herberth, M., Koethe, D., Cheng, T. M., Krzyszton, N. D. et al., Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol. Psychiatry 2011, 16, 848-859.
7. Chan, M. K., Tsang, T. M., Harris, L. W., Guest, P. C. et al., Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol. Psychiatry 2011, 16, 1189-1202.
8. Ma, D., Chan, M. K., Lockstone, H. E., Pietsch, S. R. et al., Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J. Proteome Res. 2009, 8, 3284-3297.
9. Ahmed, E. U., Ahmed, S., Ukai, W., Matsumoto, I. et al., Antipsychotic induced alteration of growth and proteome of rat neural stem cells. Neurochem. Res. 2012, 37, 1649-1659.
10. Weinberger, D. R., Berman, K. F., Zec, R. F., Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 1986, 43, 114-124.
11. Rajkowska, G., Halaris, A., Selemon, L. D., Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 2001, 49, 741-752.
12. Baxter, L. R., Jr., Schwartz, J. M., Phelps, M. E., Mazziotta, J. C. et al., Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 1989, 46, 243-250.
13. Davidson, R. J., Anxiety and affective style: role of prefrontal cortex and amygdala. Biol. Psychiatry 2002, 51, 68-80.
14. Goldstein, R. Z., Volkow, N. D., Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 2002, 159, 1642-1652.
15. Perlstein, W. M., Carter, C. S., Noll, D. C., Cohen, J. D., Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry 2001, 158, 1105-1113.
16. Cannon, T. D., Glahn, D. C., Kim, J., Van Erp, T. G. et al., Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch. Gen. Psychiatry 2005, 62, 1071-1080.
17. Bozikas, V. P., Kosmidis, M. H., Kiosseoglou, G., Karavatos, A., Neuropsychological profile of cognitively impaired patients with schizophrenia. Compr. Psychiatry 2006, 47, 136-143.
18. Breton, F., Plante, A., Legauffre, C., Morel, N. et al., The executive control of attention differentiates patients with schizophrenia, their first-degree relatives and healthy controls. Neuropsychologia 2011, 49, 203-208.
19. Lewis, D. A., Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology 1997, 16, 385-398.
20. Larsen, T. K., Melle, I., Auestad, B., Haahr, U. et al., Early detection of psychosis: positive effects on 5-year outcome. Psychol. Med. 2011, 41, 1461-1469.
21. Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J. et al., Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996, 22, 283-303.
22. Piontkewitz, Y., Arad, M., Weiner, I., Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr. Bull. 2011, 37, 1257-1269.
23. Piontkewitz, Y., Bernstein, H. G., Dobrowolny, H., Bogerts, B. et al., Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav. Immun. 2012, 26, 353-363.
24. Richtand, N. M., Taylor, B., Welge, J. A., Ahlbrand, R. et al., Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 2006, 31, 77-89.
25. Blakemore, S. J., Choudhury, S., Development of the adolescent brain: implications for executive function and social cognition. J. Child Psychol. Psychiatry 2006, 47, 296-312.
26. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
27. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A. et al., Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 2011, 10, 1794-1805.
28. Luber, C. A., Cox, J., Lauterbach, H., Fancke, B. et al., Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 2010, 32, 279-289.
29. Waanders, L. F., Chwalek, K., Monetti, M., Kumar, C. et al., Quantitative proteomic analysis of single pancreatic islets. Proc. Natl. Acad. Sci. USA 2009, 106, 18902-18907.
30. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
31. English, J. A., Pennington, K., Dunn, M. J., Cotter, D. R., The neuroproteomics of schizophrenia. Biol. Psychiatry 2011, 69, 163-172.
32. Schubert, K. O., Focking, M., Prehn, J. H., Cotter, D. R., Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol. Psychiatry 2012, 17, 669-681.
33. Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T. et al., Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20, 389-409.
34. Newcomer, J. W., Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1), 1-93.
35. Heykants, J., Huang, M. L., Mannens, G., Meuldermans, W. et al., The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 1994, 55(Suppl), 13-17.
36. van Beijsterveldt, L. E., Geerts, R. J., Leysen, J. E., Megens, A. A. et al., Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 1994, 114, 53-62.
37. Aravagiri, M., Marder, S. R., Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology 2002, 159, 424-431.
38. Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A. et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41, D1063-D1069.